Abstract 107P
Background
Although complete resection of colorectal cancer liver metastasis (CLM) is the only potentially curative treatment, surgery alone is not enough, as the recurrence rate after resection of CLM is high. Therefore, in clinical practice, adjuvant chemotherapy (AC) has been performed after resection of CLM. However, the evidence supporting the efficacy of AC after resection of CLM is not sufficient. Previous reports have noted that AC after resection of CLM is effective only in patients with a high risk of recurrence. The purpose of this study was to classify the risk of recurrence using systemic inflammatory markers, which have been reported to be associated with the clinical outcomes, and to evaluate the efficacy of AC according to the risk of recurrence.
Methods
We retrospectively reviewed the medical records of 119 patients with CLM who underwent potentially curative surgery. The C-reactive protein-to-albumin ratio (CAR) was calculated from the blood samples by dividing the serum C-reactive protein level by the serum albumin level. The optimal cut-off value of the CAR was determined according to the ROC curve analysis, and then the patients were classified into the high- or low-CAR group. We examined the relationship between the CAR and the relapse-free survival (RFS) after resection of CLM and evaluated the efficacy of AC according to the risk of recurrence.
Results
The cut-off value of the CAR was set at 0.0471 based on the ROC curve analysis. The RFS rates were significantly better in the low-CAR group than in the high-CAR group. The efficacy of AC after resection of CLM was not recognized in the low-CAR group (with a low risk of recurrence), whereas the RFS rates were significantly better for the patients who were treated with AC after resection of CLM in the high-CAR group (with a high risk of recurrence).
Conclusions
The preoperative CAR was found to be useful as prognostic markers in patients with CLM who were treated with potentially curative resection. Furthermore, it was suggested that AC after resection of CLM may be effective for preventing recurrence in patients with high inflammatory markers who have a high risk of recurrence.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Osaka City University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Impact of chemotherapy and radiotherapy on tissue expander or implant removal in breast cancer patients
Presenter: Sungmi Jung
Session: Poster display session
Resources:
Abstract
5P - Long-term prognostic effect of hormone receptor subtype on breast cancer
Presenter: Ki-tae Hwang
Session: Poster display session
Resources:
Abstract
6P - Effect of apparent diffusion coefficient in predicting pathologic responses in patients with breast cancer treated with neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel
Presenter: Yutaka Mizuno
Session: Poster display session
Resources:
Abstract
7P - Current diagnostic strategy for mammographic microcalcification without specific ultrasound abnormality
Presenter: Naoki Sato
Session: Poster display session
Resources:
Abstract
8P - Comparison of standard uptake value of 18F-FDG-PET-CT with tumour-infiltrating lymphocytes in breast cancer ≥1cm
Presenter: Soeun Park
Session: Poster display session
Resources:
Abstract
10P - Prognosis and effect of adjuvant treatment in small, node(-), HER2(+) breast cancer
Presenter: Seungtaek Lim
Session: Poster display session
Resources:
Abstract
11P - The prognosis of rare histopathologic subtype of breast cancer
Presenter: Soo Youn Bae
Session: Poster display session
Resources:
Abstract
12P - Daily collection of physical activity via smartphone application and smart band for development of distress screening tools in breast cancer survivors: A feasibility study
Presenter: Yungil Shin
Session: Poster display session
Resources:
Abstract
13P - Breast cancer distribution in East Azerbaijan, Iran: Results of population-based cancer registry
Presenter: Shima Pashaei
Session: Poster display session
Resources:
Abstract
14P - Validation of the optimum timing of assessment of tumour infiltrating lymphocytes during preoperative chemotherapy for breast cancer
Presenter: Shinichiro Kashiwagi
Session: Poster display session
Resources:
Abstract